Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N)

• Published in: Clinical genitourinary cancer 2024-10, Vol.22 (5), p.102159, Article 102159
• Main Authors: Viktor, Grünwald, Martin, Bögemann, Mohammad-Reza, Rafiyan, Günter, Niegisch, Marco, Schnabel, Anne, Flörcken, Michael, Maasberg, Christoph, Maintz, Mark-Oliver, Zahn, Anke, Wortmann, Andreas, Hinkel, Jochen, Casper, C, Darr, Thomas, Hilser, M, Schulze, Disorn, Sookthai, Philipp, Ivanyi
• Format: Article
• Language: English
• Subjects: Cabozantinib; Immune checkpoint inhibitor; Immune refractory; Metastatic renal cell carcinoma; Previously treated patients
• ISSN: 1558-7673; 1938-0682; 1938-0682
• DOI: 10.1016/j.clgc.2024.102159

Efficacy of treatment after failure of check point inhibitors (ICI) therapy remains ill-defined in metastatic renal cell carcinoma (mRCC). To evaluate the safety and effectiveness of cabozantinib after failure of ICI-based therapies. Patients with mRCC who concluded cabozantinib treatment directly after an ICI-based therapy were eligible. Data was collected retrospectively from participating sites in Germany. Cabozantinib was administered as a standard of care. Adverse events (AE) were reported according to CTCAE v5.0. Objective response rate according to RECIST 1.1 and Progression Free Survival (PFS) were collected from medical records. Descriptive statistics and Kaplan-Meyer-plots were utilized. About 56 eligible patients (71.4% male) with median age of 66 years and clear cell histology in 66.1% (n = 37) were analyzed. 87.5% (n = 49) had ≥ 2 previous lines. IMDC risk was intermediate or poor in 17 patients (30.4%) and missing in 66.1%. 20 patients (35.7%) started with 60 mg. 55.4% (n = 31) required dose reductions, 26.8% (n = 15) treatment delays and 1.8% (n = 1) treatment discontinuation. Partial response was reported in 10.7% (n = 6), stable and progressive disease were reported in 19.6% (n = 11) and in 12.5% (n = 7). 32 patients were not evaluable (57.1%). Median treatment duration was 6.1 months. Treatment related AE were reported in 76.8% (n = 43) and 19.6% (n = 11) had grade 3-5. Fatigue (26.8%), diarrhea (26.8%) and hand-foot-syndrome (25.0%) were the 3 most frequent AEs of any grade and causality. SAE were reported in 21.4% (n = 12), 2 were fatal. Major limitation was the retrospective data capture in our study. Cabozantinib followed directly after ICI-based therapy was safe and feasible. No new safety signals were reported. A lower starting dose was frequently utilized in this real-world cohort, which was associated with a favorable tolerability profile. Our data supports the use of cabozantinib after ICI treatment. Cabozantinib is a standard therapy for previously treated patients with metastatic or advanced Renal Cell Carcinoma who failed prior tyrosine kinase inhibitor therapy. The recent shift in the treatment landscape towards checkpoint inhibitor combinations created a data gap for subsequent therapies. Our real-world study suggests cabozantinib remains effective after CPI failure, with comparable efficacy to the pivotal METEOR trial.